Search

Displaying results 1281 - 1290 of 4262 in total
  1. Drug

    Mebutamate

    go.drugbank.com/drugs/DB06797
    Approved

    Mebutamate is a sedative and anxiolytic drug with anti-hypertensive (blood pressure lowering) effects comparable to those of other barbiturates but is only around 1/3rd the potency of secobarbital as a

  2. Drug

    Terlipressin

    go.drugbank.com/drugs/DB02638
    ApprovedInvestigational

    [A252672] The drug was first approved by the FDA in September 2022.[L43217]

  3. Drug

    Quinacrine

    go.drugbank.com/drugs/DB01103
    Investigational

    An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years.

  4. Drug

    Mephenytoin

    go.drugbank.com/drugs/DB00532
    ApprovedWithdrawn

    These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha.

  5. Drug

    Mangafodipir

    go.drugbank.com/drugs/DB06796
    ApprovedInvestigationalWithdrawn

    Teslascan has been removed from the Drug Product List by FDA in 2003, and withdrawn from the European market in 2012. … Enhanced contrast by mangafodipir improves visualization and detection of lesions of the liver formed from metastatic disease or hepatocellular carcinomas.

  6. Drug

    Sertaconazole

    go.drugbank.com/drugs/DB01153
    Approved

    Sertaconazole nitrate is an antifungal medication of the imidazole class. It is available in topical formulations for the treatment of skin infections such as athlete's foot.

  7. Drug

    Gadoteridol

    go.drugbank.com/drugs/DB00597
    ApprovedInvestigational

    [A263076] Initially approved by the FDA in 1992, gadoteridol received additional approval in 2020 for use in pediatric patients less than 2 years old.[L49876] … [A263076,A263081,L49871] It was 1 of the 3 macrocyclic gadolinium-based contrast agents (GBCAs) that was mandated by the EMA to replace linear gadolinium-based contrast agents due to concerns about retained

  8. Drug

    Pyridostigmine

    go.drugbank.com/drugs/DB00545
    ApprovedInvestigational

    By inhibiting the breakdown of acetylcholine in the neuromuscular junction, they increase signalling and relieve symptoms.

  9. Drug

    Carisoprodol

    go.drugbank.com/drugs/DB00395
    Approved

    This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with both aspirin and codeine [FDA label, F4060, F4069]. … Originally approved by the FDA in 1959 [FDA label], carisoprodol is a centrally acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and other medications

  10. Drug

    Melphalan

    go.drugbank.com/drugs/DB01042
    ApprovedInvestigational

    [L40928] It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.